Adamax vs Semax: A Registered Russian Nasal Drug and a Vendor Name With No Record Anywhere

Adamax is one of the newest names in the research-peptide market, and the search interest in comparing it with Semax has risen faster than almost anything else we track. The comparison is usually written as a list of claimed advantages. The more useful version asks a plainer question first: what does the public record hold for each? For Semax, a registered Russian medicine and a 2026 FDA review. For Adamax, as of tonight, nothing — and this page shows the searches that establish that, so anyone can repeat them. What Semax's dose record looks like is on our Semax dosage page; its adverse-event record is on our Semax side-effects page.

The record, side by side

What "zero" means here

The searches behind the Adamax column are simple to reproduce. PubMed, adamax[tiab], returns 39 records; we read every title. They describe Adamax, an optimisation algorithm used to train neural networks — brain-tumour classifiers, stroke detection, intrusion detection, furniture recognition. Not one concerns a peptide. ClinicalTrials.gov returns no study naming Adamax. PubChem holds no compound by the name. FDA's adverse-event database returns no report.

An absence like this is a finding in its own right. Semax also has no ClinicalTrials.gov entry — its research was done inside a Russian system that did not register trials internationally — but it has decades of papers and a regulator's file. Adamax has neither: no paper, no registry entry, no regulator. Every statement about what it is or does traces back to a business that sells it.

What the vendors say, and the one thing we could check

Vendor and enthusiast pages describe Adamax as Semax with two changes — an acetyl group at the N-terminus and an adamantane group, a rigid cage-shaped hydrocarbon, at the other end — and claim the adamantane makes the molecule more fat-soluble, more resistant to enzymes and better at crossing into the brain. Those are reasons for designing a molecule a certain way. None has been measured.

The pages are not consistent with each other. One gives a nine-residue sequence notation for a molecule said to be built on Semax's seven residues. What we could check is arithmetic. The formula vendors quote, C50H69N11O11S, works out to 1,032.2 Da with standard atomic weights — matching the 1,032.24 Da another page states, so at least the two figures agree. For comparison:

The vendor formula is C11H15NO heavier than N-acetyl Semax amidate — about 177 Da, our arithmetic. That is the right order of size for an adamantane-containing addition, but without a published structure, a register entry or an independent analysis, there is no way to confirm that what is in an Adamax vial is the molecule described. A certificate of analysis can confirm a mass; it cannot confirm a structure no reference defines — see how to read a COA.

What Semax's record holds

Semax is not a blank. It is registered in Russia as nasal drops, has a large, mostly Russian-language literature going back to the 1990s, and was reviewed by FDA's reviewers for the July 23–24, 2026 Pharmacy Compounding Advisory Committee (FDA briefing document). Their conclusion was that the clinical information was insufficient to characterise its safety; they identified eight references in which people received it, all intranasally, and only one reported on adverse events. The committee nonetheless voted 8 to 5, with one abstention, to recommend it for compounding — a recommendation FDA has not yet acted on. The full account, including the two animal findings FDA flagged on bleeding, is on our Semax side-effects page, and where Semax sits among the other cognitive peptides is on our cognitive peptides page.

So the comparison is not between a proven drug and an unproven one. It is between a compound with a thin but real record and a compound with none.

What neither record contains

• No study comparing them. No one has given Adamax and Semax to the same people, or to anyone.
• No subcutaneous human data for Semax, and none of any kind for Adamax.
• No independent structure for Adamax — no paper, patent or register entry that we found defines it.
• Nothing about research-chemical vials of either, which carry none of the controls of a registered medicine — see what research-use-only labelling means.

Peptide Lexicon's Semax entry and its N-acetyl Semax amidate entry cover what those two are. Anyone weighing either compound, or connecting a symptom to one, should take the question to a clinician; for Adamax, there is no document to bring.

Sources and dates

• PubMed E-utilities, adamax[tiab]: 39 records, every title read, none concerning a peptide; semax[tiab] AND humans[mh]: 47 records. Queried 2026-10-09.
• ClinicalTrials.gov API v2, interventions "adamax" and "semax": 0 studies each, queried 2026-10-09.
• PubChem PUG REST, names "adamax" (no compound found), "semax" (CID 9811102) and "N-acetyl semax amidate" (CID 172638603), queried 2026-10-09.
• openFDA drug adverse event endpoint, medicinal products "adamax" (no matches) and "semax" (2 reports), queried 2026-10-09 (dataset updated 2026-07-30).
• FDA. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: semax-related bulk drug substances. https://www.fda.gov/media/193348/download.
• Committee votes: American Med Spa Association, FDA Advisory Committee Recommends Adding Six of Seven Peptides to Compounding List, 2026-07-24, read 2026-10-09.
• Vendor and enthusiast descriptions of Adamax (formula C50H69N11O11S, 1,032.24 Da), read 2026-10-09 and reported as claims; formula mass calculated with standard atomic weights (C 12.011, H 1.008, N 14.007, O 15.999, S 32.06).